Berzosertib (original) (raw)
Berzosertib (VE-822, VX-970, M6620) is a drug originally invented by Vertex Pharmaceuticals and licensed to Merck KGaA, Darmstadt, Germany for development. It acts as a potent inhibitor of the enzyme ataxia telangiectasia and Rad3 related (ATR) and with lower potency as an inhibitor of ATM serine/threonine kinase (ATM). These enzymes are both involved in detecting DNA damage as part of cell cycle checkpoints during cell division. By inhibiting their activity, berzosertib interferes with the ability of rapidly dividing cells to detect damage to DNA, and this makes it useful as a potential treatment for some forms of cancer by causing accumulation of DNA damage in the cancer cells and thus reducing their viability. It has progressed furthest in trials for the treatment of ovarian cancer, tho
| Property | Value |
|---|---|
| dbo:abstract | Berzosertib (VE-822, VX-970, M6620) is a drug originally invented by Vertex Pharmaceuticals and licensed to Merck KGaA, Darmstadt, Germany for development. It acts as a potent inhibitor of the enzyme ataxia telangiectasia and Rad3 related (ATR) and with lower potency as an inhibitor of ATM serine/threonine kinase (ATM). These enzymes are both involved in detecting DNA damage as part of cell cycle checkpoints during cell division. By inhibiting their activity, berzosertib interferes with the ability of rapidly dividing cells to detect damage to DNA, and this makes it useful as a potential treatment for some forms of cancer by causing accumulation of DNA damage in the cancer cells and thus reducing their viability. It has progressed furthest in trials for the treatment of ovarian cancer, though also shows activity against numerous other cancer types. Phase 1 trial results show promising results in the first clinical trial of the drug class.The new study, designed to test the drug's safety, found that half of patients given the new drug either alone or with platinum chemotherapy saw their cancer stop growing, and two patients saw their tumors shrink or disappear completely. In a UCLA-led study, berzosertib showed promise in treating COVID-19. (en) |
| dbo:casNumber | 1232416-25-9 |
| dbo:chEBI | 131166 |
| dbo:drugbank | DB11794 |
| dbo:fdaUniiCode | L423PRV3V3 |
| dbo:kegg | D11148 |
| dbo:pubchem | 59472121 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Berzosertib_structure.png?width=300 |
| dbo:wikiPageID | 64365868 (xsd:integer) |
| dbo:wikiPageLength | 4581 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1084696991 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Cancer dbr:Vertex_Pharmaceuticals dbr:Clinical_trial dbr:COVID-19 dbr:UCLA dbr:Cell_cycle_checkpoint dbr:Cell_division dbc:Enzyme_inhibitors dbr:Ataxia_telangiectasia_and_Rad3_related dbr:ATM_serine/threonine_kinase dbr:Merck_Group dbr:Ovarian_cancer |
| dbp:atcPrefix | None (en) |
| dbp:c | 24 (xsd:integer) |
| dbp:casNumber | 1232416 (xsd:integer) |
| dbp:chebi | 131166 (xsd:integer) |
| dbp:chemspiderid | 30773968 (xsd:integer) |
| dbp:drugbank | DB11794 (en) |
| dbp:h | 25 (xsd:integer) |
| dbp:iupacName | 3 (xsd:integer) |
| dbp:kegg | D11148 (en) |
| dbp:n | 5 (xsd:integer) |
| dbp:o | 3 (xsd:integer) |
| dbp:pubchem | 59472121 (xsd:integer) |
| dbp:s | 1 (xsd:integer) |
| dbp:smiles | CCSC1=CC=CC2=CN=CN (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | JZCWLJDSIRUGIN-UHFFFAOYSA-N (en) |
| dbp:unii | L423PRV3V3 (en) |
| dbp:width | 220 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Reflist dbt:Short_description |
| dcterms:subject | dbc:Enzyme_inhibitors |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Berzosertib (VE-822, VX-970, M6620) is a drug originally invented by Vertex Pharmaceuticals and licensed to Merck KGaA, Darmstadt, Germany for development. It acts as a potent inhibitor of the enzyme ataxia telangiectasia and Rad3 related (ATR) and with lower potency as an inhibitor of ATM serine/threonine kinase (ATM). These enzymes are both involved in detecting DNA damage as part of cell cycle checkpoints during cell division. By inhibiting their activity, berzosertib interferes with the ability of rapidly dividing cells to detect damage to DNA, and this makes it useful as a potential treatment for some forms of cancer by causing accumulation of DNA damage in the cancer cells and thus reducing their viability. It has progressed furthest in trials for the treatment of ovarian cancer, tho (en) |
| rdfs:label | Berzosertib (en) |
| owl:sameAs | wikidata:Berzosertib https://global.dbpedia.org/id/2Y3sJ |
| prov:wasDerivedFrom | wikipedia-en:Berzosertib?oldid=1084696991&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Berzosertib_structure.png |
| foaf:isPrimaryTopicOf | wikipedia-en:Berzosertib |
| is dbo:wikiPageRedirects of | dbr:C24H25N5O3S |
| is dbo:wikiPageWikiLink of | dbr:C24H25N5O3S dbr:Ataxia_telangiectasia_and_Rad3_related |
| is foaf:primaryTopic of | wikipedia-en:Berzosertib |
